A-674563 can blcok the tumor cell proliferation with EC50 of 0.4 uM. A-674563 inhibit the phosphorylation of Akt downstream targets in a dose-dependent manner. In STS cells, A-674563 inhibit Akt and induce G2 cell cycle arrest and apoptosis.
In vivo
20 mg/kg A-674563 increases plasma insulin in an oral glucose tolerance test. A-674563 shows no significant monotherapy tumor inhibitory activity; the efficacy of the combination therapy is significantly improved compared to paclitaxel monotherapy.